drugset / Trial / NCT05432388
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
RandomizedParallel-groupTriple-blindTreatment
Summary
A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy was measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.
Timeline
- Start
- 2022-10-12
- Primary completion
- 2025-03-11
- Completion
- 2025-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remibrutinib | Small molecule | 10 mg | Oral |
| Subject | Remibrutinib | Small molecule | 25 mg | Oral |
| Subject | Remibrutinib | Small molecule | 100 mg | Oral |